Compare BSL & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSL | BWAY |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.1M | 337.9M |
| IPO Year | N/A | 2019 |
| Metric | BSL | BWAY |
|---|---|---|
| Price | $13.49 | $19.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 71.9K | 67.9K |
| Earning Date | 01-01-0001 | 11-11-2025 |
| Dividend Yield | ★ 9.55% | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | ★ $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ N/A | $59.95 |
| Revenue Growth | N/A | ★ 27.08 |
| 52 Week Low | $12.19 | $7.84 |
| 52 Week High | $14.56 | $19.80 |
| Indicator | BSL | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 35.83 | 62.54 |
| Support Level | $13.50 | $18.31 |
| Resistance Level | $13.59 | $19.80 |
| Average True Range (ATR) | 0.07 | 0.87 |
| MACD | -0.00 | 0.14 |
| Stochastic Oscillator | 15.38 | 79.63 |
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.